{
    "Average Volume": "1,642,939",
    "Description": "Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.",
    "Dividend Ex-Date": "N/A",
    "EPS": "-4.76",
    "Forward Dividend": "N/A (N/A)",
    "Industry": "Diagnostics & Research",
    "Last Updated": "2021-05-12 14:07",
    "Market Cap": "16.369B",
    "Next Earnings Date": "Jul 28, 2021 - Aug 02, 2021",
    "PE Ratio": "N/A",
    "Sector": "Healthcare",
    "Stock Type": "Company",
    "Symbol": "EXAS",
    "Website": "http://www.exactsciences.com",
    "Year Range": "70.75 - 159.54"
}